Trade EyePoint Pharmaceuticals, Inc. - EYPT CFD
Market information is presented
as of 2023-09-21
- Summary
Spread | - | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
EyePoint Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 2.19-15.63 |
Average Volume (10 days) | 601.24K |
Average Volume (3 months) | 12.31M |
Market Cap | 351.94M |
P/E Ratio | -100.00K |
Shares Outstanding | 34.98M |
Revenue | 37.33M |
EPS | -2.83 |
Dividend (Yield %) | N/A |
Beta | 1.35 |
Next Earnings Date | Oct 31, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
Date | Close | Change | Change (%) | Open | High | Low |
---|
EyePoint Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, September 26, 2023 | ||
Time (UTC) 17:15 | Country US
| Event EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare ConferenceForecast -Previous - |
Tuesday, October 10, 2023 | ||
Time (UTC) 17:45 | Country US
| Event EyePoint Pharmaceuticals Inc at JonesTrading Healthcare Summit EyePoint Pharmaceuticals Inc at JonesTrading Healthcare SummitForecast -Previous - |
Tuesday, October 31, 2023 | ||
Time (UTC) 12:30 | Country US
| Event Q3 2023 EyePoint Pharmaceuticals Inc Earnings Release Q3 2023 EyePoint Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Thursday, February 29, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 EyePoint Pharmaceuticals Inc Earnings Release Q4 2023 EyePoint Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 41.404 | 36.939 | 34.437 | 20.365 | 2.928 |
Revenue | 41.404 | 36.939 | 34.437 | 20.365 | 2.928 |
Total Operating Expense | 142.6 | 90.15 | 72.632 | 72.036 | 27.487 |
Selling/General/Admin. Expenses, Total | 60.324 | 53.078 | 45.429 | 47.711 | 17.075 |
Research & Development | 49.642 | 28.5 | 17.424 | 15.368 | 10.412 |
Unusual Expense (Income) | 22.258 | -2.065 | 1.495 | 3.81 | |
Operating Income | -101.196 | -53.211 | -38.195 | -51.671 | -24.559 |
Interest Income (Expense), Net Non-Operating | -1.058 | -5.206 | -7.199 | -5.122 | -20.161 |
Net Income Before Taxes | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Net Income After Taxes | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Net Income Before Extra. Items | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Net Income | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Income Available to Common Excl. Extra. Items | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Income Available to Common Incl. Extra. Items | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Diluted Net Income | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Diluted Weighted Average Shares | 37.317 | 28.758 | 12.836 | 10.4307 | 8.5057 |
Diluted EPS Excluding Extraordinary Items | -2.74015 | -2.03133 | -3.53646 | -5.44479 | -5.25765 |
Diluted Normalized EPS | -2.14369 | -2.10314 | -3.37403 | -5.07952 | -5.25765 |
Total Extraordinary Items | |||||
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Cost of Revenue, Total | 8.326 | 8.177 | 5.824 | 2.687 | |
Gross Profit | 33.078 | 28.762 | 28.613 | 17.678 | |
Depreciation / Amortization | 2.05 | 2.46 | 2.46 | 2.46 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 9.105 | 7.683 | 10.533 | 10.012 | 11.565 |
Revenue | 9.105 | 7.683 | 10.533 | 10.012 | 11.565 |
Cost of Revenue, Total | 1.792 | 0.64 | 3.41 | 1.405 | 1.734 |
Gross Profit | 7.313 | 7.043 | 7.123 | 8.607 | 9.831 |
Total Operating Expense | 33.213 | 29.237 | 54.268 | 28.41 | 30.781 |
Selling/General/Admin. Expenses, Total | 14.635 | 15.27 | 14.411 | 15.228 | 15.44 |
Research & Development | 15.439 | 13.327 | 15.543 | 11.162 | 12.992 |
Depreciation / Amortization | 0 | 0 | 0.205 | 0.615 | 0.615 |
Operating Income | -24.108 | -21.554 | -43.735 | -18.398 | -19.216 |
Interest Income (Expense), Net Non-Operating | 1.188 | 0.39 | 0.283 | -0.022 | -0.19 |
Net Income Before Taxes | -22.92 | -21.164 | -43.452 | -18.42 | -19.406 |
Net Income After Taxes | -22.92 | -21.164 | -43.452 | -18.42 | -19.406 |
Net Income Before Extra. Items | -22.92 | -21.164 | -43.452 | -18.42 | -19.406 |
Net Income | -22.92 | -21.164 | -43.452 | -18.42 | -19.406 |
Income Available to Common Excl. Extra. Items | -22.92 | -21.164 | -43.452 | -18.42 | -19.406 |
Income Available to Common Incl. Extra. Items | -22.92 | -21.164 | -43.452 | -18.42 | -19.406 |
Diluted Net Income | -22.92 | -21.164 | -43.452 | -18.42 | -19.406 |
Diluted Weighted Average Shares | 37.576 | 37.486 | 37.353 | 37.338 | 37.322 |
Diluted EPS Excluding Extraordinary Items | -0.60996 | -0.56458 | -1.16328 | -0.49333 | -0.51996 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.57412 | -0.56458 | -0.60913 | -0.49333 | -0.51996 |
Unusual Expense (Income) | 1.347 | 0 | 20.699 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 172.808 | 237.745 | 63.118 | 41.717 | 47.601 |
Cash and Short Term Investments | 144.561 | 211.558 | 44.909 | 22.214 | 45.261 |
Cash & Equivalents | 95.633 | 178.593 | 44.909 | 22.214 | 45.261 |
Short Term Investments | 48.928 | 32.965 | |||
Total Receivables, Net | 15.503 | 18.354 | 9.453 | 11.368 | 0.627 |
Accounts Receivable - Trade, Net | 15.503 | 18.354 | 9.453 | 11.368 | 0.627 |
Prepaid Expenses | 9.858 | 4.217 | 3.419 | 5.997 | 1.434 |
Total Assets | 180.356 | 263.372 | 91.717 | 72.971 | 78.168 |
Property/Plant/Equipment, Total - Net | 7.398 | 2.728 | 3.24 | 3.435 | 0.288 |
Property/Plant/Equipment, Total - Gross | 9.505 | 3.984 | 4.268 | 4.274 | 0.983 |
Accumulated Depreciation, Total | -2.107 | -1.256 | -1.028 | -0.839 | -0.695 |
Intangibles, Net | 0 | 22.749 | 25.209 | 27.669 | 30.129 |
Other Long Term Assets, Total | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
Total Current Liabilities | 34.537 | 23.658 | 14.888 | 11.52 | 21.459 |
Accounts Payable | 5.919 | 7.385 | 4.811 | 4.192 | 2.64 |
Accrued Expenses | 16.902 | 15.067 | 9.013 | 7.313 | 18.789 |
Notes Payable/Short Term Debt | 10.475 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.205 | 1.069 | 0.945 | 0.015 | 0.03 |
Total Liabilities | 83.988 | 78.992 | 73.176 | 64.641 | 40.535 |
Total Long Term Debt | 29.31 | 36.598 | 38.048 | 47.223 | 17.621 |
Other Liabilities, Total | 20.141 | 18.736 | 20.24 | 5.898 | 1.455 |
Total Equity | 96.368 | 184.38 | 18.541 | 8.33 | 37.633 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.034 | 0.034 | 0.018 | 0.109 | 0.095 |
Additional Paid-In Capital | 766.899 | 752.602 | 528.362 | 472.667 | 445.192 |
Retained Earnings (Accumulated Deficit) | -671.351 | -569.097 | -510.68 | -465.286 | -408.493 |
Other Equity, Total | 0.786 | 0.841 | 0.841 | 0.84 | 0.839 |
Total Liabilities & Shareholders’ Equity | 180.356 | 263.372 | 91.717 | 72.971 | 78.168 |
Total Common Shares Outstanding | 34.0829 | 33.9058 | 18.14 | 10.9417 | 9.53722 |
Long Term Debt | 29.31 | 36.562 | 37.977 | 47.223 | 17.621 |
Total Inventory | 2.886 | 3.616 | 5.337 | 2.138 | 0.279 |
Current Port. of LT Debt/Capital Leases | 0.036 | 0.137 | 0.119 | ||
Capital Lease Obligations | 0 | 0.036 | 0.071 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 146.057 | 172.808 | 192.102 | 205.866 | 219.629 |
Cash and Short Term Investments | 122.483 | 144.561 | 157.259 | 171.167 | 190.784 |
Cash & Equivalents | 105.765 | 95.633 | 75.362 | 82.134 | 101.545 |
Total Receivables, Net | 10.422 | 15.503 | 20.876 | 22.594 | 19.589 |
Accounts Receivable - Trade, Net | 10.422 | 15.503 | 20.876 | 22.594 | 19.589 |
Total Inventory | 4.071 | 2.886 | 3.531 | 3.254 | 3.336 |
Prepaid Expenses | 9.081 | 9.858 | 10.436 | 8.851 | 5.92 |
Total Assets | 154.593 | 180.356 | 220.49 | 233.433 | 244.555 |
Property/Plant/Equipment, Total - Net | 8.386 | 7.398 | 7.334 | 5.898 | 2.642 |
Property/Plant/Equipment, Total - Gross | 9.505 | 6.589 | 5.057 | 2.367 | |
Accumulated Depreciation, Total | -2.107 | -0.206 | -0.172 | -0.138 | |
Intangibles, Net | 0 | 20.904 | 21.519 | 22.134 | |
Other Long Term Assets, Total | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
Total Current Liabilities | 27.242 | 34.537 | 34.256 | 33.39 | 31.971 |
Accounts Payable | 9.453 | 5.919 | 6.112 | 7.058 | 7.302 |
Accrued Expenses | 11.239 | 16.902 | 16.429 | 14.613 | 12.97 |
Notes Payable/Short Term Debt | 5.295 | 10.475 | 10.475 | 10.475 | 10.475 |
Current Port. of LT Debt/Capital Leases | 0.036 | 0.07 | 0.105 | 0.122 | |
Other Current Liabilities, Total | 1.255 | 1.205 | 1.17 | 1.139 | 1.102 |
Total Liabilities | 76.203 | 83.988 | 84.14 | 82.067 | 77.736 |
Total Long Term Debt | 29.37 | 29.31 | 29.251 | 29.181 | 29.126 |
Long Term Debt | 29.37 | 29.31 | 29.251 | 29.181 | 29.108 |
Capital Lease Obligations | 0 | 0 | 0 | 0.018 | |
Other Liabilities, Total | 19.591 | 20.141 | 20.633 | 19.496 | 16.639 |
Total Equity | 78.39 | 96.368 | 136.35 | 151.366 | 166.819 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.034 | 0.034 | 0.034 | 0.034 | 0.034 |
Additional Paid-In Capital | 770.028 | 766.899 | 763.562 | 760.209 | 756.07 |
Retained Earnings (Accumulated Deficit) | -692.515 | -671.351 | -627.899 | -609.479 | -590.073 |
Other Equity, Total | 0.843 | 0.786 | 0.653 | 0.602 | 0.788 |
Total Liabilities & Shareholders’ Equity | 154.593 | 180.356 | 220.49 | 233.433 | 244.555 |
Total Common Shares Outstanding | 34.3019 | 34.0829 | 34.0722 | 34.0526 | 34.0471 |
Short Term Investments | 16.718 | 48.928 | 81.897 | 89.033 | 89.239 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -102.254 | -58.417 | -45.394 | -56.793 | -44.72 |
Cash From Operating Activities | -65.005 | -50.097 | -14.435 | -56.699 | -22.586 |
Cash From Operating Activities | 0.396 | 0.311 | 0.189 | 0.144 | 0.097 |
Amortization | 2.05 | 2.46 | 2.46 | 2.46 | 1.229 |
Non-Cash Items | 37.826 | 7.288 | 8.174 | 10.026 | 21.748 |
Cash Taxes Paid | |||||
Changes in Working Capital | -3.023 | -1.739 | 20.136 | -12.536 | -0.94 |
Cash From Investing Activities | -17.265 | -33.121 | -0.362 | -0.213 | -0.132 |
Capital Expenditures | -2.15 | -0.156 | -0.362 | -0.213 | -0.132 |
Other Investing Cash Flow Items, Total | -15.115 | -32.965 | 0 | 0 | |
Cash From Financing Activities | -0.69 | 216.902 | 37.492 | 33.864 | 29.204 |
Issuance (Retirement) of Stock, Net | 0.395 | 217.198 | 50.212 | 23.041 | 29.399 |
Foreign Exchange Effects | 0 | 0.001 | -0.001 | ||
Net Change in Cash | -82.96 | 133.684 | 22.695 | -23.047 | 6.485 |
Cash Interest Paid | 2.6 | 4.846 | 5.51 | 4.87 | 1.241 |
Financing Cash Flow Items | -3.188 | -0.15 | -0.918 | -19.177 | -0.195 |
Issuance (Retirement) of Debt, Net | 2.103 | -0.146 | -11.802 | 30 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -21.164 | -102.254 | -58.802 | -40.382 | -20.976 |
Cash From Operating Activities | -16.835 | -65.005 | -52.417 | -39.281 | -20.158 |
Cash From Operating Activities | 0.105 | 0.396 | 0.266 | 0.17 | 0.081 |
Amortization | 0 | 2.05 | 1.845 | 1.23 | 0.615 |
Non-Cash Items | 2.806 | 37.826 | 12.157 | 9.172 | 5.146 |
Cash Interest Paid | 0.74 | 2.6 | 1.907 | 1.349 | 0.941 |
Changes in Working Capital | 1.418 | -3.023 | -7.883 | -9.471 | -5.024 |
Cash From Investing Activities | 32.086 | -17.265 | -50.182 | -56.454 | -56.442 |
Capital Expenditures | -0.484 | -2.15 | -1.565 | -0.367 | -0.149 |
Cash From Financing Activities | -5.119 | -0.69 | -0.632 | -0.724 | -0.448 |
Financing Cash Flow Items | -0.169 | -3.188 | -3.164 | -3.138 | -2.896 |
Issuance (Retirement) of Stock, Net | 0.248 | 0.395 | 0.395 | 0.241 | 0.241 |
Issuance (Retirement) of Debt, Net | -5.198 | 2.103 | 2.137 | 2.173 | 2.207 |
Net Change in Cash | 10.132 | -82.96 | -103.231 | -96.459 | -77.048 |
Other Investing Cash Flow Items, Total | 32.57 | -15.115 | -48.617 | -56.087 | -56.293 |
Foreign Exchange Effects |
EyePoint Pharmaceuticals, Inc. Company profile
About Eyepoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a pharmaceutical company that is focused on developing and commercializing therapeutics to help improve eye disorders. The Company's products include EYP-1901, YUTIQ50, DEXYCU and YUTIQ. EYP-1901, which combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor. EYP-1901 is in Phase I clinical trial and targeting treatment of wet age-related macular degeneration for additional indications in diabetic retinopathy and retinal vein occlusion. DEXYCU is a single-dose treatment for postoperative inflammation following ocular surgery. YUTIQ50 is a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. It is utilizing its core technology platform, Durasert to deliver drugs and biologics to treat chronic diseases.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Eyepoint Pharmaceuticals Inc revenues increased 7% to $36.9M. Net loss increased 29% to $58.4M. Revenues reflect DEXYCU segment increase from $7M to $18.4M, YUTIQ segment increase of 22% to $17M, United States segment increase of 59% to $36M. Higher net loss reflects Research and Development Expense increase of 64% to $26.2M (expense), General and administrative increase of 19% to $20.7M (expense).
Equity composition
Common Stock $0.001 Par, 02/11, 60M auth., 20,741,392 issd. Insiders own 11.62%. 8/04 :49,804,381 shs issd @ $1.09each to pSiMedica Ltd on acquisition. 06/08, Name changed from pSivida Limited. 06/08, 1-for-40 reverse stock split.
Industry: | Pharmaceuticals (NEC) |
480 Pleasant St Ste B300
WATERTOWN
MASSACHUSETTS 02472-2468
US
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com